Atopic Eczema (Localized Refractory)
Investigational use for localized refractory atopic dermatitis; very limited case-series evidence.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for atopic eczema. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for atopic eczema is investigational.
- What evidence exists?
- Tier C (investigational). One small case series (n=12) reported SCORAD reductions in localized refractory atopic dermatitis after 3 sessions. There are no randomized controlled trials. Evidence-based first-line care includes emollients, topical corticosteroids, topical calcineurin inhibitors, and for moderate-to-severe disease dupilumab or upadacitinib (all supported by extensive RCT data).
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness around eczematous plaques for 5 to 10 days
- Itching and irritation at bite sites for days to weeks (may be prolonged in atopic skin)
- Local skin infection or, rarely, Aeromonas infection (heightened in patients with eczema due to skin barrier disruption and S. aureus colonization)
- Post-inflammatory hyperpigmentation more common in atopic patients
- Allergic reaction to leech saliva (uncommon, but atopic patients have higher background atopy)
- Small permanent scars at bite sites
- Potential to trigger an eczema flare at or near application sites
- Who should not consider this
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with eczema herpeticum or active impetiginization (skin infection emergencies)
- Patients on systemic immunomodulators (higher infection risk)
- Patients with widespread severe atopic dermatitis where systemic therapy is clearly indicated
- Children — evidence base does not support pediatric use
- What to ask your clinician
- Have I been evaluated by a dermatologist?
- Have I had adequate trials of emollients, topical steroids, topical calcineurin inhibitors, or dupilumab/upadacitinib?
- What evidence supports leech therapy for atopic eczema specifically?
- What is the risk of triggering a flare or infection in compromised skin?
- What is the realistic chance of benefit, and for how long?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- When to seek urgent care
- Rapidly worsening eczema with painful clustered blisters (possible eczema herpeticum — emergency)
- Spreading redness, warmth, pus, weeping, or red streaks (impetiginization or cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for atopic eczema.
- A single 12-patient case series is not evidence of efficacy in the general population.
- Mechanism rationale (local anti-inflammation) does NOT establish clinical efficacy.
- Atopic skin has a disrupted barrier and is at high risk for infection — leech bites add risk.
- Leech therapy is not a substitute for emollients, topical therapy, or dupilumab/upadacitinib.
Safety cross-references
Clinical Profile
- Category
- dermatological
- ICD-10
- L20.0, L20.81, L20.84, L20.89, L20.9
- Safety tier
- medium
Evidence Summary
Evidence is limited to a single small open-label trial without a control group (Shankar & Rao 2014, PMID 25593404, n=27) in which a minimum of four leech applications at 7-day intervals were associated with a 55% reduction in the SCORAD index, a 54.45% reduction in the Eczema Area and Severity Index (EASI), and a 62.36% improvement in Dermatology Life Quality Index (DLQI), all P<0.01, with no adverse reactions reported (according to PubMed; DOI: https://doi.org/10.4103/0257-7941.147432). Because the study was uncontrolled and small, these results cannot establish efficacy. Generalized atopic dermatitis is not appropriate for leech therapy, and standard care (emollients, topical corticosteroids, topical calcineurin inhibitors, and dupilumab or upadacitinib for moderate-to-severe disease) remains the standard. Leech bite sites may show post-inflammatory hyperpigmentation. ASH position: investigational only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Krishnan B et al. (2019), n=12
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Eczema herpeticum or active impetiginization
- Severe ongoing immunomodulator therapy
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.